TELO
Telomir Pharmaceuticals, Inc.
$1.27
-0.03 (-2.31%)
At close · Jul 2
Market Cap
$87.34M
Shares
68,774,956
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.27
Open$1.31
Day$1.27–1.34
52W$1.05–3.10
Avg vol 30d84K
Short int942K · 1.4% float · 10.1d
Short vol32%
DataFeb 2024–Jul 2026
Filing10-Q · May 14
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−6% below
◦
Price vs 50-day avg
−2% below
◦
RSI (14)
50 · neutral
+
MACD trend
positive
−
52-week position
11% · near low
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $1 › 200d $1 — 200d above 50d
−
Institutional flow
-18% holders QoQ · +5 funds added
◦
Insider flow
No net insider activity over 90 days
−
Short interest
1.37% of float · ▲ +2.1% MoM · 10.1 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
27 holders — mid 2-yr range
Fundamentals
Excellent
+
EPS growth
+41% Y/Y
+
Balance sheet
net cash $1.3M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−6% below
Bearish
Price vs 50-day avg
−2% below
Neutral
RSI (14)
50 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
11% · near low
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-18% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.37% of float · ▲ +2.1% MoM · 10.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
27 holders — mid 2-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 11%
52-wk high $3
vs 200-day avg -6%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TELO
this stock
Telomir Pharmaceuticals, Inc.
|
$87.34M | -4.5% | — | — | 1.4% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TELO | +3.3% | +3.3% | -10.6% | -0.8% | -4.5% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +1.8% | +4.5% | -18.6% | -0.5% | -13.7% |